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Introduction
A variety of management strategies have been reported
for midtrimester pregnancy interruption [1,2]. Tech-
niques include dilatation and evacuation, intra-amniotic
prostaglandin F2α instillation, prostaglandin E2 (PGE2)
vaginal suppositories, intravenous high-dose oxytocin
[3,4], a sulprostone infusion [5], and vaginal or oral
administration of misoprostol [6–8]. Misoprostol, a
potent uterotropic and uterotonic agent, which causes
cervical effacement and dilation, and stimulates myome-
trial contractions, is effective in interrupting midtrimes-
ter pregnancies at gestational ages of 12–28 weeks.
Several recent comparative investigations have demon-
strated that the use of high-dose oral or vaginal miso-
prostol is more efficacious than alternative methods,
such as concentrated oxytocin and PGE2 administration,
for interrupting midtrimester pregnancies, with an ac-
ceptable side-effect profile [9,10]. A high-dose, vaginal
misoprostol regimen was superior to concentrated oxy-
tocin plus low-dose PGE2 in terms of the significantly
shortened induction-to-delivery interval, fewer side ef-
fects, less medication for treatment of side effects, and
a lower incidence of retained placenta requiring curet-
tage [10]. Furthermore, compared with concentrated
oxytocin plus low-dose vaginal misoprostol, high-dose
vaginal misoprostol significantly shortened the time to
induction of midtrimester labor in a later randomized
trial [11].
Misoprostol may be administered via the oral, vagi-
nal, or sublingual route. According to the pharmacoki-
netics of misoprostol [12,13], the sublingual and oral
routes have the faster onset of action than vaginal
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Objective: This pilot study retrospectively evaluated the outcomes of medical induction of termination of
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rhea, which was easily relieved by medication.
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administration, with or without water. Because the mi-
soprostol tablet was developed for oral administration
and not sublingual administration, most patients who
take misoprostol sublingually experience an unpleasant
taste. Therefore, oral administration is the easiest and
has the greatest acceptability among women.
The ultimate goal of a successful strategy for inter-
rupting midtrimester pregnancies is to combine efficacy
(a shortened interval from induction to delivery) with
minimal side effects and fewer cases of a retained pla-
centa. Titrated oral misoprostol for induction of labor
in the third trimester was more able to overcome the
barrier of the cervix with no case of induction failure
compared with vaginal misoprostol in our previous
study [14]. Furthermore, because labor induction with
a titrated oral misoprostol solution is effective and safe,
it has been used as the standard method in our obstetric
unit since 2004. Oral administration of misoprostol
hourly was chosen because oral absorption is more
rapid and possibly more predictable, with a peak serum
concentration after oral administration of 34 minutes
and a half-life of 20–40 minutes [13]. We reviewed
patients who had undergone hourly oral misoprostol
treatment for midtrimester pregnancy interruption at
our labor and delivery unit to evaluate and analyze the
outcomes.
Materials and Methods
We retrospectively reviewed the records of all women
with living fetuses at 12–25 weeks of gestational age who
electively underwent labor induction with hourly oral
misoprostol administration to interrupt a midtrimester
pregnancy at the Labor and Delivery Unit of China
Medical University Beigang Hospital (Beigang, Taiwan)
over a 4-year period from July 2004 to June 2008. Indi-
vidual clinical case records were examined to confirm
their authenticity and to collect details on management
and outcomes. Women were excluded if clinical chorio-
amnionitis or spontaneous labor (regular uterine con-
tractions with cervical change) were encountered. This
study was approved by the institutional review board.
After patients without uterine surgery were admit-
ted to our delivery unit and evaluated, we explained to
them the method of hourly oral misoprostol adminis-
tration to interrupt the pregnancy and its side effects
including nausea, vomiting, diarrhea, and fever. The
risk of uterine rupture was also discussed. Initially, one
tablet of misoprostol 200μg was given orally every hour.
If the fetus had not been delivered within 12 hours, the
oral dosage of misoprostol was increased to 400 μg/hr,
from the 13th dose until expulsion of the fetus. Induction
failure was defined as no fetal expulsion within 36 hours
of initiation of induction. All side effects were recorded
by obstetric nurses and were relieved using appropriate
medication prescribed by the on-duty physician. If the
placenta had not been delivered within 30 minutes after
expulsion of the fetus, a retained placenta was recorded,
and curettage was immediately performed.
The primary study outcomes for the investigation
were the number of women who delivered their fetus
vaginally within 12, 24 and 36 hours upon initiation of
induction, the induction-to-delivery interval, and the
total dosage of misoprostol administered. Secondary
outcomes assessed included maternal side effects and
complications. The entry characteristics of the patients
including age, height, weight, parity, gestational age 
at induction, and fetal weight and birth length post-
induction were also recorded. Descriptive statistics
were use to analyze these data.
Results
Sixteen pregnant women (11 nullipara and 5 multipara)
who met the entry criteria were reviewed in this study.
Their demographic characteristics are given in Table 1.
All 16 women electively underwent induction for psy-
chosocial reasons. Eight women had completed vagi-
nal delivery within 12 hours (50.0%; 3 nullipara and 
5 multipara), and 13 had completed vaginal delivery
within 24 hours (81.3%; 8 nullipara and 5 multipara).
All 16 women had completed vaginal delivery within
36 hours (Table 2).
The median induction-to-delivery interval of all
women was 12.0 hours (range, 6.3–30.9 hours). The
median induction-to-delivery interval was 15.7 hours
(range, 6.7–30.9 hours) for the nullipara group and
9.1 hours (range, 6.3–9.8 hours) for the multipara
group. The median total dosage was 2,600 μg (range,
1,400–9,800 μg), while the median total dosage was
3,600 μg (range, 1,400–9,800 μg) for the nulliparous
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Table 1. Maternal and fetal demographics (n = 16)*
Nullipara : Multipara 11 : 5
Age (yr) 18.2 (13.0–39.3)
Height (cm) 159 (146–170)
Weight (kg) 52 (40–74)
Gestation (wk) 17.0 (12.0–24.0)
Fetal weight (g) 100.0 (10.0–800.0)
Fetal birth length (cm) 19 (12–30)
*Data are presented as n or mean (range).
group and 1,800 μg (range, 1,400–2,000 μg) for the
multiparous group.
Common side effects included diarrhea (50.0%),
nausea and vomiting (12.5%), and pyrexia (12.5%). No
shivering was seen. One woman (6.3%) required curet-
tage due to a retained placenta (Table 3).
Discussion
Misoprostol is a strong agent which has uterotropin and
uterotonin effects, and multiple trials have shown that
misoprostol is an effective agent for cervical ripening
and labor induction. Therefore, we developed a new
hourly oral method of administering misoprostol, ac-
cording to the mathematical model of the time to the
peak serum concentration (Tmax), half-life (T1/2) after
absorption, and uterine responsiveness.
Misoprostol does not affect the hepatic mixed-
function oxidase enzyme systems. In patients with
varying degrees of renal impairment, an approximate
doubling of T1/2, peak serum concentration (Cmax), and
area under the serum concentration curve were found
when compared with normal patients, but no clear cor-
relation between the degree of impairment and area
under the serum concentration curve was shown. No
routine dosage adjustment is recommended in older
patients or patients with renal impairment. Misoprostol
does not produce clinically significant effects on serum
levels of prolactin, gonadotropin, thyroid-stimulating
hormone, growth hormone, thyroxine, cortisol, gastro-
intestinal hormones, creatinine, or uric acid. Neither
gastric emptying, immunologic competence, platelet ag-
gregation, pulmonary function, nor the cardiovascular
system is modified by the recommended doses of miso-
prostol. Therefore, the use of misoprostol is not contra-
indicated with renal disease, severe anemia, systemic
lupus erythematosus, hypertension, or heart disease.
Parameters used to assess the efficacy of misopros-
tol were the interval from the first misoprostol dose to
vaginal delivery, the percentage of women who delivered
infants vaginally within 24 hours upon induction initi-
ation, and the induction failure rate. It needs to be
pointed out that our study did not include women with
a dead fetus, because it is easier to successfully terminate
a pregnancy via the vagina with a dead fetus than a liv-
ing fetus. Our outcomes showed that the induction-to-
delivery interval (12.0 hours) was shorter than that with
a high-dose oral regimen (15.2 hours), which included
dead fetuses [9]. Furthermore, in our study, 13 women
(81.3%) including eight nulliparous and five multiparous
women had completed vaginal termination within 
24 hours. Induction failure did not occur among our
cases. It is evident that the hourly oral regimen used for
case management in our study was highly effective.
Parameters used to assess the safety were the total
dosage and side effects of misoprostol. It needs to be
understood that the safety of misoprostol has been
documented at doses of up to 1,600 μg per day [15],
but even higher dosages have been used with only mild
side effects seen. To avoid misoprostol toxicity, induc-
tion failure was defined as no fetal expulsion within 
36 hours of initiation of induction in our study. The max-
imum total dosage in our study group was 9,800 μg in
a nulliparous woman, who experienced only the side
effect of diarrhea. The most common side effect in our
study was diarrhea (50.0%), which was tolerable due
to the lack of recurrence after the pregnancy had been
terminated. The side effects of pyrexia and shivering
common in other studies with a high-dose oral or vagi-
nal regimen were rare in our study. Only two women ex-
perienced pyrexia in our study group. One needed a total
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Table 2. Outcomes of labor induction*
Outcome Nullipara (n = 11) Multipara (n = 5) Total (n = 16)
Vaginal delivery within 12 hr 3 (27.3) 5 (100) 8 (50.0)
Vaginal delivery within 24 hr 8 (72.7) 5 (100) 13 (81.3)
Vaginal delivery within 36 hr 11 (100) 5 (100) 16 (100)
Induction-to delivery interval (hr) 15.7 (6.7–30.9) 9.1 (6.3–9.8) 12.0 (6.3–30.9)
Total dosage of misoprostol (μg) 3600 (1,400–9,800) 1800 (1,400–2,000) 2600 (1,400–9,800)
*Data are presented as n (%) or median (range).
Table 3. Adverse obstetric outcomes (n = 16)*
Retained placenta requiring curettage 1 (6.3)
Side effect
Nausea 2 (12.5)
Vomiting 2 (12.5)
Diarrhea 8 (50.0)
Shivering 0 (0)
Pyrexia 2 (12.5)
*Data are presented as n (%).
dosage of 5,800 μg and the other needed 1,400 μg. In
published case reports [16–18], accidental overdosing
with misoprostol resulting in hyperthermia, hypoxia, and
rhabdomyolysis all occurred with a single intake at a
dosage exceeding 3,000 μg. Therefore, a probable rea-
son for fewer side effects in our study was the steady
serum level of misoprostol acid achieved with our regi-
men due to the 1 hour oral dosing interval with a small
dosage. Thus the toxicity of misoprostol resulting from
Cmax can be avoided. However, one needs to remain
alert to the possibility of misoprostol toxicity when the
symptoms of pyrexia and shivering appear.
Uterine rupture and a retained placenta are two
complications with the use of misoprostol. Even with-
out a history of uterine surgery, a case of uterine rupture
in a second trimester termination in combination with
mifepristone was documented [19]. There was no case
of uterine rupture in our study group. The usual reason
for a retained placenta is failure of the retroplacental
myometrium to contract, thus preventing detachment
[20]. The retained placenta rate was 6.3% (1/16) in our
study, which was lower than that with high-dose oral
misoprostol in another study [9]. The method of hourly
oral misoprostol suggests that steady contractions of the
entire myometrium including the retroplacental site can
be achieved by maintaining a steady serum concentra-
tion of misoprostol acid to avoid such a complication.
Further study with more cases is required to prove this
hypothesis.
Development of an optimal regimen for medical in-
duction to terminate midtrimester pregnancies is ongo-
ing. An ideal regimen is one that is effective, inexpensive,
and easy to administer, and rapidly results in vaginal
delivery. This pilot study suggests that hourly oral miso-
prostol administration is a promising method for termi-
nating midtrimester pregnancies. Therefore, conducting
a randomized controlled trial is required to compare
hourly oral and high-dose vaginal misoprostol admin-
istration for interrupting midtrimester pregnancies.
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